Literature DB >> 32313642

"Treat and repair" strategy for shunt lesions: a critical review.

Balaji Arvind1, Jay Relan1, Shyam S Kothari1.   

Abstract

The issue of operability in patients with shunt lesions and raised pulmonary vascular resistance is contentious. Several reports suggest that patients traditionally considered inoperable may be operated after treatment with targeted drug therapy for pulmonary arterial hypertension. We reviewed all the published literature of "treat and repair" approach to gain more insights into the utility of this approach. A critical appraisal of the published literature suggests that this approach is less established for patients with post tricuspid shunts, and for patients with pre-tricuspid shunts with modestly elevated indexed pulmonary vascular resistance (possibly greater than 11 WU.m2). Targeted drug therapy may be able to extend the therapeutic window in carefully selected patients, but its use as a routine in this setting seems unwarranted.
© The Author(s) 2020.

Entities:  

Keywords:  Eisenmenger syndrome; Pulmonary artery hypertension; congenital heart disease; operability

Year:  2020        PMID: 32313642      PMCID: PMC7153197          DOI: 10.1177/2045894020917885

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  47 in total

1.  Successful shunt closure and improvement of hemodynamics in an ASD patient with severe pulmonary arterial hypertension and small shunt following a long-term use of bosentan.

Authors:  Nobuhiro Tahara; Minori Mizoguchi; Akihiro Honda; Atsuko Tahara; Yoshikazu Nitta; Norihiro Kodama; Hiroshi Koiwaya; Shigeaki Aoyagi; Tsutomu Imaizumi
Journal:  Int J Cardiol       Date:  2011-11-10       Impact factor: 4.164

2.  Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report.

Authors:  Konrad Hoetzenecker; Hendrik J Ankersmit; Diana Bonderman; Wolfram Hoetzenecker; Reinald Seitelberger; Walter Klepetko; Irene M Lang
Journal:  J Thorac Cardiovasc Surg       Date:  2008-09-09       Impact factor: 5.209

3.  Measurement, interpretation and use of hemodynamic parameters.

Authors:  Antonio A Lopes; Patrick W O'Leary
Journal:  Cardiol Young       Date:  2009-05       Impact factor: 1.093

4.  Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension.

Authors:  Gian Paolo Ussia; Massimiliano Mulè; Elio Caruso; Rosa Aiello; Corrado Tamburino
Journal:  Int J Cardiol       Date:  2006-07-27       Impact factor: 4.164

5.  2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Karen K Stout; Curt J Daniels; Jamil A Aboulhosn; Biykem Bozkurt; Craig S Broberg; Jack M Colman; Stephen R Crumb; Joseph A Dearani; Stephanie Fuller; Michelle Gurvitz; Paul Khairy; Michael J Landzberg; Arwa Saidi; Anne Marie Valente; George F Van Hare
Journal:  J Am Coll Cardiol       Date:  2018-08-16       Impact factor: 24.094

6.  Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.

Authors:  Rosa Laura E van Loon; Marcus T R Roofthooft; Hans L Hillege; Arend D J ten Harkel; Magdalena van Osch-Gevers; Tammo Delhaas; Livia Kapusta; Jan L M Strengers; Lukas Rammeloo; Sally-Ann B Clur; Barbara J M Mulder; Rolf M F Berger
Journal:  Circulation       Date:  2011-09-26       Impact factor: 29.690

7.  Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.

Authors:  Adaani E Frost; Miguel A Quiñones; William A Zoghbi; George P Noon
Journal:  J Heart Lung Transplant       Date:  2005-04       Impact factor: 10.247

8.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Authors:  Gerald Simonneau; Robyn J Barst; Nazzareno Galie; Robert Naeije; Stuart Rich; Robert C Bourge; Anne Keogh; Ronald Oudiz; Adaani Frost; Shelmer D Blackburn; James W Crow; Lewis J Rubin
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

9.  Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?

Authors:  Rosa Laura E van Loon; Elke S Hoendermis; Marielle G J Duffels; Anton Vonk-Noordegraaf; Barbara J M Mulder; Hans L Hillege; Rolf M F Berger
Journal:  Am Heart J       Date:  2007-10       Impact factor: 4.749

10.  Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Authors:  Tomás Pulido; Igor Adzerikho; Richard N Channick; Marion Delcroix; Nazzareno Galiè; Hossein-Ardeschir Ghofrani; Pavel Jansa; Zhi-Cheng Jing; Franck-Olivier Le Brun; Sanjay Mehta; Camilla M Mittelholzer; Loïc Perchenet; B K S Sastry; Olivier Sitbon; Rogério Souza; Adam Torbicki; Xiaofeng Zeng; Lewis J Rubin; Gérald Simonneau
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

View more
  1 in total

1.  The Treatment Strategy for the Atrial Septal Defect in the Presence of Severe Pulmonary Hypertension.

Authors:  Evelina Zarambaitė; Grytė Ramantauskaitė; Aušra Krivickienė; Adakrius Siudikas; Skaidrius Miliauskas; Eglė Ereminienė
Journal:  Medicina (Kaunas)       Date:  2022-07-02       Impact factor: 2.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.